Wells Fargo downgraded Hyperfine from Overweight to Equal Weight and set a new price target of $2.40 from $8.00 previously

Evercore ISI initiated coverage of Hyperfine with a rating of Outperform and set a new price target of $7.00

Wells Fargo initiated coverage of Hyperfine with a rating of Overweight and set a new price target of $8.00

8-K - Hyperfine, Inc. (0001833769) (Filer)

8-K - Hyperfine, Inc. (0001833769) (Filer)

424B5 - Hyperfine, Inc. (0001833769) (Filer)

10-Q - Hyperfine, Inc. (0001833769) (Filer)

8-K - Hyperfine, Inc. (0001833769) (Filer)

8-K - Hyperfine, Inc. (0001833769) (Filer)

DEFA14A - Hyperfine, Inc. (0001833769) (Filer)

DEF 14A - Hyperfine, Inc. (0001833769) (Filer)

S-8 - Hyperfine, Inc. (0001833769) (Filer)

10-K - Hyperfine, Inc. (0001833769) (Filer)

Latest Swoop® System software delivers a substantial leap in image quality for AI-powered portable MR brain imaging. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the world's first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced FDA clearance of its next-generation software. This tenth-generation release delivers a substantial leap in image quality for ultra-low-field MR imaging. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250528571999/en/Comparison of Swoop® system FLAIR images showing current image quality and ne

Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced plans to present at the upcoming Jefferies Global Healthcare Conference on Thursday, June 5th at 4:20pm Eastern Time (ET). Management will also be hosting in-person meetings on Wednesday, June 4th. To schedule a one-on-one meeting with management, please reach out to your Jefferies representative, or the investor contact below. About Hyperfine, Inc. and the Swoop® Portable MR Imaging® System Hyperfine, Inc. (NASDAQ:HYPR) is the groundbreaking health technol

GUILFORD, Conn., May 13, 2025 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced first quarter 2025 financial results and provided a business update. "Our commercial efforts have primarily focused on the hospital business, where we've continued to experience longer and more variable sales cycles in the first quarter. During this time, we also made meaningful progress in expanding our pipeline, now including promising early opportunities in the neurology office setting. We're enthusiastic

Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the first quarter 2025 on Tuesday, May 13, 2025. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call. About the Swo

Real-world study will assess clinical utility and patient experience across diverse neurological conditions to support adoption of AI-powered portable MRI systems in the office setting. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system, first approved in 2021—today announced the enrollment of initial patients in the NEURO PMR (Neurological Evaluation in the Office with Portable MRI) study. The NEURO PMR study is the first multi-center, prospective observational study of its kind, comparing portable ultra-low-field MRI and

GUILFORD, Conn., March 17, 2025 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced fourth quarter and full year 2024 financial results and provided a business update. "I am pleased with the many milestones we achieved in the fourth quarter of 2024. These set the stage well for us to execute on our expansion plan, drive accelerated growth across multiple sites of care globally and meaningfully reduce cash burn in 2025," said Maria Sainz, Chief Executive Officer and President of Hyperfine,

Collaboration aims to make portable MRI faster, smarter, and more accessible worldwide. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced a strategic collaboration with NVIDIA. This collaboration leverages NVIDIA AI expertise and accelerated computing to enhance Hyperfine portable imaging technology—making brain MRI faster, smarter, and more affordable on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250317452571/en/The AI-powered

Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the fourth quarter and full year 2024 on Monday, March 17, 2025. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call

Hyperfine, Inc. (NASDAQ:HYPR) ("Hyperfine" or the "Company") today announced it has entered into a definitive agreement with investors for the purchase and sale of 4,511,278 shares of the Company's Class A common stock and warrants to purchase up to 4,511,278 shares of Class A common stock. Each share of Class A common stock and accompanying warrant were sold together at a combined offering price of $1.33 in a registered direct offering. The warrants have an exercise price of $1.33 per share, are immediately exercisable and will expire five years from the initial exercise date. All of the securities in the offering are being sold by Hyperfine. The gross proceeds to Hyperfine from the offe

Two presentations at ISC build on a growing body of data demonstrating the value of AI-powered portable MR images in providing information to aid physicians in the diagnosis of acute ischemic stroke, including data from the ACTION PMR stroke study. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the world's first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced the presentation of two studies at the 2025 International Stroke Conference (ISC), which provide evidence supporting the value of AI-powered portable MRI in acute ischemic stroke triage and diagnosis. Nota

4 - Hyperfine, Inc. (0001833769) (Issuer)

4 - Hyperfine, Inc. (0001833769) (Issuer)

4 - Hyperfine, Inc. (0001833769) (Issuer)

4 - Hyperfine, Inc. (0001833769) (Issuer)

4 - Hyperfine, Inc. (0001833769) (Issuer)

4 - Hyperfine, Inc. (0001833769) (Issuer)

4/A - Hyperfine, Inc. (0001833769) (Issuer)

4 - Hyperfine, Inc. (0001833769) (Issuer)

4 - Hyperfine, Inc. (0001833769) (Issuer)

4 - Hyperfine, Inc. (0001833769) (Issuer)

Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the first quarter 2025 on Tuesday, May 13, 2025. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call. About the Swo

Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the fourth quarter and full year 2024 on Monday, March 17, 2025. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call

GUILFORD, Connecticut, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced third quarter 2024 financial results and provided a business update. "The Hyperfine team delivered yet another strong quarter of financial performance across revenue growth, gross margin expansion, and disciplined cash management while executing against several important priorities in our plans to expand into new sites of care and internationally," said Maria Sainz, Chief Executive Officer and President of Hy

Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the third quarter 2024 on Tuesday, November 12, 2024. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call. About th

─ Reports $3.6M in Q2 2024 Revenue; 50% Gross Margin─ Raises FY 2024 Revenue Guidance to $13-16M GUILFORD, Conn., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced second quarter 2024 financial results and provided a business update. "I am proud of the Hyperfine team, achieving record revenue and delivering meaningful progress across innovation and clinical initiatives in the quarter," said Maria Sainz, Chief Executive Officer and President of Hyperfine, Inc. "The opportunities ahead

Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the second quarter 2024 on Thursday, August 8, 2024. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the presentation will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call. Abou

GUILFORD, Conn., May 13, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced first quarter 2024 financial results and provided a business update. "We have kicked off 2024 strong. I am pleased with our commercial progress shown by sales across US and international accounts, as well as the important milestones we hit in Q1 by commencing CARE PMR study enrollment in Alzheimer's and launching our 8th generation AI-powered software," said Maria Sainz, Chief Executive Officer and President of Hyperfin

Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the first quarter 2024 on Monday, May 13, 2024. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the presentation will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call. About the

GUILFORD, Conn., March 21, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced fourth quarter and full year 2023 financial results and provided a business update. "I am pleased with our strong growth in 2023. We continued to drive adoption in our beachhead markets of critical care and pediatrics, and we made significant progress to expand our use cases through clinical evidence and innovation," said Maria Sainz, Chief Executive Officer and President of Hyperfine, Inc. "We remain focused on our 3

Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the world's first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system, today announced that it will report financial results for the fourth quarter and full year 2023 on Thursday, March 21, 2024. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the presentation will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the st

SC 13G - Hyperfine, Inc. (0001833769) (Subject)

SC 13G/A - Hyperfine, Inc. (0001833769) (Subject)

SC 13G/A - Hyperfine, Inc. (0001833769) (Subject)

SC 13D/A - Hyperfine, Inc. (0001833769) (Subject)

SC 13G - Hyperfine, Inc. (0001833769) (Subject)

SC 13G/A - Hyperfine, Inc. (0001833769) (Subject)

SC 13D - Hyperfine, Inc. (0001833769) (Subject)

Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to the QuidelOrtho Board QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the "Board"), effective December 6, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210769572/en/R. Scott Huennekens (Photo: Business Wire) T

Two new executive roles position Hyperfine to drive the adoption of the Swoop® system in hospital settings and expand into the office setting, laying the foundation for significant growth in 2025 and beyond. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced the appointment of Chi Nguyen as Vice President of Office Strategy and Partnerships and Rafael Donnay as Vice President of Hospital Strategy and Health Economics to provide leadership in key growth areas. These strategic leadership appointments bolster t

Strategic focus on India aims to make the Swoop® portable MR brain imaging system commercially available in a vast and underserved MRI market Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced it has entered into a distribution agreement with Radiosurgery Global, Ltd. to develop the market in India. The distribution agreement also includes the countries of Malaysia, Indonesia, and Singapore through future expansion, offering Hyperfine, Inc. a significantly increased presence in Asia. The clinical value of the Swoop®

- Distributors appointed in France, the United Kingdom, and Italy - Industry veteran Enrico Barini joins as International Business Development Director Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced it has entered into agreements with three experienced and accomplished distributors to support commercial expansion plans of the Swoop® system into European markets with an initial focus on France, the United Kingdom, and Italy. In 2023, Hyperfine, Inc. obtained CE certification under the EU MDR and UKCA certificati

BUFFALO, N.Y., Nov. 29, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII) ("22nd Century" or the "Company"), a biotechnology company focused on utilizing advanced plant technologies to improve health and wellness, today announced the appointment of Lawrence (Larry) Firestone as the Company's Chairman and Chief Executive Officer. Nora Sullivan, former Chair of the Board, commented, "Larry is a seasoned executive known for his 'hands-on' leadership style emphasizing teamwork, business alignment, continuous improvement, cost control and process optimization. His track record of success with fast growing public companies will serve 22nd Century well as it continues to execu

In addition to the study, the company appoints a world-class stroke advisory board as part of its acute ischemic stroke initiatives Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking medical device company that created the Swoop® system, the world's first FDA-cleared portable magnetic resonance brain imaging system, has announced the commencement of an international, multi-site observational study, ACTION PMR (ACuTe Ischemic strOke detectioN with Portable MR). To support its acute stroke care initiatives, Hyperfine Inc. has formed an advisory board of world-renowned stroke experts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2

SAN JOSE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital health solutions, announced today the appointment of Tamara Elias, M.D., Senior Vice President at Nuance, and Scott Huennekens, executive chairperson at Hyperfine, Wondr Medical, Acutus Medical and Envista Holdings Corporation, to the BrightInsight Advisory Council. Dr. Elias and Huennekens bring deep and complimentary experience to this group of industry experts, who work with BrightInsight leadership to advance the company's vision to transform patient outcomes globally through the power of digital technology. Dr. Elias and Huennek

GUILFORD, Conn., June 14, 2022 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (NASDAQ:HYPR), creator of the Swoop® Portable MR Imaging System™, the world's first US FDA-cleared portable magnetic resonance imaging (MRI) device, announced today that it has completed registration and notification of the device in Australia and New Zealand. With this activity, the Swoop system is now available for purchase in Australia and New Zealand and includes the US FDA-cleared advanced reconstruction software using deep learning. Multiple pilot research units have been ordered across key Australian cities bolstering Hyperfine's entry into these two markets and laying the foundation for commercial efforts. Hyperfin

Former Google Health Executive to Expand Cardiovascular Strategy for Ocular Health Technology Company Tesseract Health, a health technology company developing a portable, non-invasive platform to detect health conditions through the eyes, proudly announces the appointment of Michael McConnell, MD, MSEE, as Tesseract's Head of Cardiovascular and Digital Health. This key role completes Tesseract's leadership team and coincides with a series of critical, strategic hires under the helm of CEO Vicky Demas, PhD. Dr. McConnell was brought on to leverage Tesseract's technology to guide the expansion of its cardiovascular strategy. In this role, he is poised to lead and champion the design, planni

GUILFORD, Conn., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Hyperfine Inc. (NASDAQ:HYPR), creator of Swoop®, the first FDA-cleared portable magnetic resonance imaging (MRI) system™, today announced the appointment of Dr. Chip Truwit as senior medical director. For more than 30 years, Truwit has committed his talents to clinical practice in public sector healthcare and neuroradiology education. "We feel privileged to welcome Dr. Truwit to the Hyperfine team," Khan Siddiqui, M.D., Hyperfine's chief medical officer and chief strategy officer, said. "His remarkable experience in neuroradiology and his work with underserved communities will make considerable contributions to the Hyperfine mission of in